Hill-Rom (NYSE:HRC) issued an update on its second quarter 2020
Pre-Market earnings guidance on Friday morning. The company provided earnings per share guidance of 1.14-1.16 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.24. The company issued revenue guidance of $699.916-707.058 million, compared to the consensus revenue estimate of $723.04 million.Hill-Rom also updated its FY 2020
Pre-Market guidance to 5.50-5.56 EPS.
NYSE HRC traded down $4.57 during trading on Friday, hitting $108.24. The company’s stock had a trading volume of 33,330 shares, compared to its average volume of 290,087. Hill-Rom has a 52 week low of $93.88 and a 52 week high of $117.10. The firm has a market cap of $7.36 billion, a P/E ratio of 48.22, a price-to-earnings-growth ratio of 1.76 and a beta of 0.83. The firm has a 50 day moving average price of $112.77 and a 200 day moving average price of $106.61. The company has a quick ratio of 1.10, a current ratio of 1.31 and a debt-to-equity ratio of 1.13.
Hill-Rom (NYSE:HRC) last announced its quarterly earnings data on Friday, November 1st. The medical technology company reported $1.69 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.65 by $0.04. Hill-Rom had a return on equity of 21.67% and a net margin of 5.24%. The company had revenue of $782.80 million for the quarter, compared to analyst estimates of $759.14 million. During the same quarter last year, the firm earned $1.63 EPS. Hill-Rom’s revenue for the quarter was up 3.1% compared to the same quarter last year. On average, equities analysts expect that Hill-Rom will post 5.53 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 16th were paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 0.78%. The ex-dividend date was Friday, December 13th. Hill-Rom’s dividend payout ratio is currently 16.54%.
A number of equities analysts have commented on HRC shares. Needham & Company LLC reissued a buy rating and issued a $131.00 price objective on shares of Hill-Rom in a research note on Friday. Morgan Stanley upgraded Hill-Rom from an equal rating to an equal weight rating and boosted their target price for the stock from $113.00 to $138.00 in a research report on Tuesday, December 17th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $122.60.
In related news, SVP Andreas G. Frank sold 6,000 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $105.83, for a total value of $634,980.00. Following the completion of the sale, the senior vice president now owns 40,004 shares in the company, valued at $4,233,623.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Deborah Rasin sold 4,739 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $103.97, for a total value of $492,713.83. Following the completion of the sale, the senior vice president now owns 31,001 shares of the company’s stock, valued at approximately $3,223,173.97. The disclosure for this sale can be found here. Corporate insiders own 0.65% of the company’s stock.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
See Also: How to Invest in an Index Fund
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.